Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 4/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PMM2 | O15305 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315486 | 0.83 | NOTUM (0.59) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL561046 | 0.80 | NOTUM (0.68) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL4293579 | 0.79 | CYP1A2 (0.57) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL5758541 | 0.79 | ELANE (0.59) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL596533 | 0.76 | CYP1A2 (0.54) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL560874 | 0.75 | ELANE (0.57) | CYP1A2NOTUMGSRELANEHTT | |
| SCHEMBL17537376 | 0.74 | CYP1A2 (0.58) | CYP1A2NOTUMBRD9GAAAR | |
| SCHEMBL597447 | 0.74 | CYP1A2 (0.52) | CYP1A2NOTUMGSRELANEBRD9 | |
| SCHEMBL15766459 | 0.74 | HSD17B10 (0.49) | CYP1A2NOTUMGSRBRD9GAA | |
| SCHEMBL984085 | 0.74 | NOTUM (0.64) | CYP1A2NOTUMGSRELANEBRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | CYP1A2 654/4885NOTUM 2654/4885GSR 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.